HC Wainwright Has Bullish Outlook for CLDX FY2026 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Investment analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Celldex Therapeutics in a report released on Friday, November 6th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings per share of ($4.05) for the year, up from their prior forecast of ($4.23). HC Wainwright currently has a “Buy” rating and a $64.00 target price on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($4.17) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q4 2026 earnings at ($0.99) EPS and FY2027 earnings at ($4.28) EPS.

Several other brokerages also recently commented on CLDX. Wells Fargo & Company raised their target price on Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Guggenheim upped their price target on Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Stifel Nicolaus set a $68.00 price target on shares of Celldex Therapeutics in a report on Tuesday, September 22nd. Barclays raised their price objective on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Cantor Fitzgerald boosted their price objective on shares of Celldex Therapeutics from $61.00 to $72.00 and gave the company an “overweight” rating in a research note on Tuesday, September 22nd. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $64.08.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX opened at $31.24 on Tuesday. The business’s fifty day moving average is $32.77 and its 200 day moving average is $32.70. The firm has a market cap of $2.45 billion, a price-to-earnings ratio of -7.27 and a beta of 1.04. Celldex Therapeutics has a 52-week low of $22.10 and a 52-week high of $45.14.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.06. The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.72 million.

Institutional Investors Weigh In On Celldex Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Diversified Trust Co grew its position in Celldex Therapeutics by 2.9% during the third quarter. Diversified Trust Co now owns 32,239 shares of the biopharmaceutical company’s stock worth $1,045,000 after buying an additional 909 shares in the last quarter. Fisher Asset Management LLC raised its holdings in shares of Celldex Therapeutics by 26.5% in the 3rd quarter. Fisher Asset Management LLC now owns 1,246,855 shares of the biopharmaceutical company’s stock valued at $40,411,000 after acquiring an additional 261,178 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Celldex Therapeutics by 11.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 111,489 shares of the biopharmaceutical company’s stock valued at $3,613,000 after acquiring an additional 11,037 shares in the last quarter. Three Bridge Wealth Advisors LLC purchased a new stake in shares of Celldex Therapeutics in the 3rd quarter valued at about $40,000. Finally, Candriam S.C.A. boosted its position in shares of Celldex Therapeutics by 7.8% during the 3rd quarter. Candriam S.C.A. now owns 518,476 shares of the biopharmaceutical company’s stock valued at $16,865,000 after acquiring an additional 37,351 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells.

The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity.

Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.